These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 8759619)

  • 1. Anti-estrogens enhance the therapeutic effect of lymphokine-activated killer cells on the P815 murine mastocytoma.
    Baral E; Nagy E; Kangas L; Berczi I
    Int J Cancer; 1996 Aug; 67(4):580-5. PubMed ID: 8759619
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination immunotherapy of the P815 murine mastocytoma with killer cells, IL-2 and anti-estrogens.
    Baral E; Nagy E; Kangas L; Berczi I
    Anticancer Res; 1997; 17(5A):3653-8. PubMed ID: 9413218
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-estrogens potentiate the immunotherapy of the P815 murine mastocytoma by cytotoxic T lymphocytes.
    Nagy E; Baral E; Kangas L; Berczi I
    Anticancer Res; 1997; 17(2A):1083-8. PubMed ID: 9137453
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapy of the SL2-5 murine lymphoma with natural killer cells and tamoxifen or toremifene.
    Baral E; Nagy E; Kangas L; Berczi I
    Anticancer Res; 1997; 17(1A):77-83. PubMed ID: 9066633
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination therapy of the H2712 murine mammary carcinoma with cytotoxic T lymphocytes and anti-estrogens.
    Baral E; Nagy E; Kangas L; Berczi I
    Anticancer Res; 1997; 17(5A):3647-51. PubMed ID: 9413217
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modulation of lymphokine-activated killer cell-mediated cytotoxicity by estradiol and tamoxifen.
    Baral E; Nagy E; Berczi I
    Int J Cancer; 1996 Apr; 66(2):214-8. PubMed ID: 8603814
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiestrogens sensitize human ovarian and lung carcinomas for lysis by autologous killer cells.
    Baral E; Nagy E; Krepart GV; Lotocki RJ; Unruh HW; Berczi I
    Anticancer Res; 2000; 20(3B):2027-31. PubMed ID: 10928146
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergistic effect of Nocardia rubra cell wall skeleton and recombinant interleukin 2 for in vivo induction of lymphokine-activated killer cells.
    Miyazaki K; Yasumoto K; Yano T; Matsuzaki G; Sugimachi K; Nomoto K
    Cancer Res; 1991 Oct; 51(19):5261-5. PubMed ID: 1833049
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Generation of lymphokine-activated killer cells in strain 2 guinea pigs and their use in the therapy of L2C, an acute B-cell leukemia.
    Gregg EO; Gregg IC; Green I
    Cancer Res; 1987 Feb; 47(3):723-9. PubMed ID: 3492265
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of cancer immunotherapy with indomethacin and interleukin-2 on murine hemopoietic stem cells.
    Saarloos MN; Khoo NK; Lala PK
    Cancer Res; 1992 Dec; 52(23):6452-62. PubMed ID: 1423293
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of immunotherapy with allogeneic lymphokine-activated killer cells and recombinant interleukin 2 on established pulmonary and hepatic metastases in mice.
    Shiloni E; Lafreniere R; Mulé JJ; Schwarz SL; Rosenberg SA
    Cancer Res; 1986 Nov; 46(11):5633-40. PubMed ID: 3489526
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Local conditions in the host influence immunotherapy with interleukin-2 and LAK cells.
    Steller EP; Ottow RT; Eggermont AM; Marquet RL; Sugarbaker PH
    Cancer Detect Prev; 1988; 12(1-6):81-90. PubMed ID: 3263202
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heterogeneity of lymphokine-activated killer cells induced by IL-2. Separate lymphoid subpopulations lyse tumor, allogeneic blasts, and modified syngeneic blasts.
    LeFor AT; Eisenthal A; Rosenberg SA
    J Immunol; 1988 Jun; 140(11):4062-9. PubMed ID: 3259603
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo antitumor activity of anti-CD3-induced activated killer cells.
    Yun YS; Hargrove ME; Ting CC
    Cancer Res; 1989 Sep; 49(17):4770-4. PubMed ID: 2527087
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhancement of murine lymphokine-activated killer cell activity by retinoic acid.
    Lin TH; Chu TM
    Cancer Res; 1990 May; 50(10):3013-8. PubMed ID: 1970751
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interactive effects of alpha-interferon A/D and interleukin 2 on murine lymphokine-activated killer activity: analysis at the effector and precursor level.
    Chikkala NF; Lewis I; Ulchaker J; Stanley J; Tubbs R; Finke JH
    Cancer Res; 1990 Feb; 50(4):1176-82. PubMed ID: 2297766
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin-2 in vivo: survival benefit and mechanisms of tumor escape in mice undergoing immunotherapy.
    Mulé JJ; Ettinghausen SE; Spiess PJ; Shu S; Rosenberg SA
    Cancer Res; 1986 Feb; 46(2):676-83. PubMed ID: 3484431
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic administration of recombinant interleukin-6 in mice induces proliferation of lymphoid cells in vivo.
    Puri RK; Leland P
    Lymphokine Cytokine Res; 1992 Jun; 11(3):133-9. PubMed ID: 1391232
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IL-4 regulation of murine lymphokine-activated killer activity in vitro. Effects on the IL-2-induced expansion, cytotoxicity, and phenotype of lymphokine-activated killer effectors.
    Mulé JJ; Krosnick JA; Rosenberg SA
    J Immunol; 1989 Jan; 142(2):726-33. PubMed ID: 2783444
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monoclonal antibody therapy of murine lymphoma: enhanced efficacy by concurrent administration of interleukin 2 or lymphokine-activated killer cells.
    Schultz KR; Klarnet JP; Peace DJ; Cheever MA; Badger CC; Bernstein ID; Greenberg PD
    Cancer Res; 1990 Sep; 50(17):5421-5. PubMed ID: 2386946
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.